LA ROCHE PHARMA
ActiveLA ROCHE PHARMA has been active since 2009 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €852k and a net result of €100k. Equity remains stable across the filed fiscal years (±1% per year). Its solvency ranks better than 42% of 8592 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
Checked score
Score 2025
91
/ 100
Excellent▲ +14 vs 2024
The score combines four axes. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability59▲+18
Solvency86▲+26
Growth78=
Stability100
Bankruptcy probability, 12 months
0.6%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €75k at 30 days acceptable
Liquidity ample (current ratio 1.92 against 1.1 in 2024), but 56.8% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
43.2%
Return on assets
5.1%
Age of the figures
8 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-08-2026, 28 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
28 d late
2024
1 d early
2023
30 d late
2022
28 d late
2021
30 d late
2020
17 d late
2019
55 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
15-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€100k▲ 38.9%
2024 · €72k
2018: €66k
2019: €71k
2020: €73k
2021: €26k
2022: €54k
2023: €52k
2024: €72k
2018 → 2025
Working capital
€406k▲ 387%
2024 · €83k
2018: €-41k
2019: €-41k
2020: €-37k
2021: €86k
2022: €136k
2023: €223k
2024: €83k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€703k-€756k▲ 7.4%€808k▲ 6.9%€878k▲ 8.7%€852k▼ 3.0%
Operating result€99k-€145k▲ 46.1%€141k▼ 2.9%€179k▲ 27.1%€214k▲ 19.5%
Net result€26k-€54k▲ 103%€52k▼ 3.6%€72k▲ 38.8%€100k▲ 38.9%
Result per fiscal year
Operating resultNet result
After the dip in 2023 the operating result has climbed two years in a row; 2025 is 20% above 2024 and is the highest year so far.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €1.97M
Fixed assets
€1.12M▼ 21.6%
Current assets
€847k▼ 7.5%
Equity and liabilities €1.97M
Equity
€852k▼ 3.0%
Debt
€1.12M▼ 23.9%
The debt ratio falls from 62.6% to 56.8%: debt falls faster than equity shrinks.
Key figures and ratios
EBITDA
€387k▲
2024 · €375k
Cash flow
€273k▲
2024 · €268k
Solvency
43.2%▲
2024 · 37.4%
Current ratio
1.92▲
2024 · 1.10
Quick ratio
1.42▲
2024 · 0.84
Debt / equity
1.31▼
2024 · 1.67
ROE
11.7%▲
2024 · 8.2%
ROA
5.1%▲
2024 · 3.1%
Interest coverage
10.89▲
2024 · 10.04
Debt
€1.12M▼
2024 · €1.47M
Debt ≤ 1 year
€442k▼
2024 · €833k
Debt > 1 year
€663k▲
2024 · €615k
Income taxes
€84k▲
2024 · €72k
Staff costs
€144k▲
2024 · €124k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€2.35M€1.97M▼
Fixed assets21/28€1.43M€1.12M▼
Intangible fixed assets21€787k€648k▼
Tangible fixed assets22/27€643k€474k▼
Land and buildings22€637k€432k▼
Furniture and vehicles24€6k€42k▲
Current assets29/58€916k€847k▼
Stocks and contracts in progress3€219k€220k▲
Stocks30/36€219k€220k▲
Amounts receivable within one year40/41€110k€141k▲
Trade receivables40€110k€141k▲
Cash at bank and in hand54/58€586k€482k▼
Deferred charges and accrued income490/1€735€5k▲
Equity and liabilities
Total equity and liabilities10/49€2.35M€1.97M▼
Equity10/15€878k€852k▼
Contributions10/11€100k€100k=
Reserves13€629k€603k▼
Distributable reserves133€629k€603k▼
Profit (loss) carried forward14€149k€149k=
Amounts payable17/49€1.47M€1.12M▼
Amounts payable after more than one year17€615k€663k▲
Financial debts170/4€366k€414k▲
Other amounts payable178/9€249k€249k=
Amounts payable within one year42/48€833k€442k▼
Current portion of amounts payable after more than one year42€134k€80k▼
Financial debts43€14k€14k▼
Credit institutions430/8€14k€14k▼
Trade debts44€129k€150k▲
Suppliers440/4€129k€150k▲
Taxes, remuneration and social security45€56k€68k▲
Taxes450/3€47k€48k▲
Remuneration and social security454/9€9k€20k▲
Other amounts payable47/48€501k€130k▼
Accrued charges and deferred income492/3€21k€14k▼
Income statement
Code20242025
Remuneration, social security and pensions62€124k€144k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€196k€173k▼
Other operating charges640/8€9k€6k▼
Gross operating margin9900€508k€537k▲
Operating profit (loss)9901€179k€214k▲
Financial income75/76B€3k€6k▲
Recurring financial income75€3k€6k▲
Financial charges65/66B€37k€36k▼
Recurring financial charges65€37k€36k▼
Profit (loss) for the period before taxes9903€144k€184k▲
Income taxes67/77€72k€84k▲
Profit (loss) for the period9904€72k€100k▲
Profit (loss) for the period to be appropriated9905€72k€100k▲
Appropriation of the result
Profit (loss) to be appropriated9906€223k€249k▲
Profit (loss) brought forward from the previous period14P€151k€149k▼
Transfer from equity791/2-€126k
Transfer to equity691/2€72k€100k▲
To other reserves6921€72k€100k▲
Profit to be distributed694/7€2k€126k▲
Return on contributions (dividend)694€2k€126k▲
Social balance
Average headcount (FTE)90872.31.6▼
The notes to these accounts (22 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
28-08
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 28 days late
2025
31-12
Financial
Highest result since 2018net €100k ▲38.9%
Operating result €214k, net result €100k, both a record.
30-07
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
30-08
NBB filing
Annual accounts filed
fiscal year 2023 · full schema · 30 days late
2023
28-08
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 28 days late
2022
30-08
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 30 days late
2021
31-12
Financial
Weakest financial yearnet €26k ▼63.9%
Net result drops to €26k, the lowest in the series; recovery starts the following year.
17-08
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema · 17 days late
2020
24-09
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema · 55 days late
2019
30-08
NBB filing
Annual accounts filed
fiscal year 2018 · full schema · 30 days late
2018
17-07
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
11-08
NBB filing
Annual accounts filed
fiscal year 2016 · full schema · 11 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
3 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, La Roche-en-Ardenne · 1 establishment unit since 2009
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Place du Marché 66980 La Roche-en-ArdenneGround area
297 m²
Building footprint
85 m²
Parcel 83031A0208/00G000, Wallonia. Linked by address, not a title deed.
1 establishment unit
LA ROCHE PHARMA
since 20092.178.471.926
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 83031A0208/00G000 | Wallonia | 297 m² | 1 · 85 m² | - |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
HOUBEN MANAGEMENT
BE 0834.345.104
Dilsen-Stokkem · Eq €852k
NIALI
BE 0874.244.073
Mechelen · Eq €851k
APOTHEEK MONNENS
BE 0434.654.525
Maaseik · Eq €851k
APOTHEEK VELTEM_PHARMA
BE 0428.228.967
Herent · Eq €853k
PHARMACIE GEERINCK - PIERRARD
BE 0472.314.081
Philippeville · Eq €853k
Of 5,209 companies in sector 47730 we hold annual accounts for 3,851. 3,124 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded11-05-2009
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
70200Business and other management consultancy
70220Business consulting
64200Holdings
64210Activities of holding companies
Sources
Crossroads Bank for EnterprisesNational Bank · 16 filingsAddress and cadastre registers
Data from official sources, last processed on 13-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
2 entriesE-mail:defoyjulien@yahoo.fr
Phone:0475/94.41.29